Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,739 | 231 | 1,479 |
| Samples | 369 | 73 | 288 |
| Peptides | 287 | 53 | 239 |
Function
MATK · Megakaryocyte-associated tyrosine kinase
The protein encoded by this gene has amino acid sequence similarity to Csk tyrosine kinase and has the structural features of the CSK subfamily: SRC homology SH2 and SH3 domains, a catalytic domain, a unique N terminus, lack of myristylation signals, lack of a negative regulatory phosphorylation site, and lack of an autophosphorylation site. This protein is thought to play a significant role in the signal transduction of hematopoietic cells. It is able to phosphorylate and inactivate Src family kinases, and may play an inhibitory role in the control of T-cell proliferation. This protein might be involved in signaling in some cases of breast cancer. Three alternatively spliced transcript variants that encode different isoforms have been described for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 254 amino-acid changes on canonical ENST00000310132 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MATK · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MATK – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 16/612 3% |
| Other Solid Cancers | 1/94 1% | 37/1515 2% |
| Melanoma | 6/210 3% | 34/1899 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 15/1390 1% |
| Gastric Carcinoma | 4/74 5% | 22/1809 1% |
| Colorectal Carcinoma | 2/143 1% | 44/3239 1% |
| Neuroendocrine Tumour | 7/154 5% | 2/577 0% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Bladder Carcinoma | 2/58 3% | 9/956 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 8/810 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 13/1592 1% |
| Meningioma | 0/3 0% | 2/252 1% |
| Glioma | 0/52 0% | 16/2127 1% |
| Hepatocellular Carcinoma | 0/46 0% | 16/2210 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Non-Cancerous | 3/104 3% | 2/830 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 10/2534 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Kidney Carcinoma | 0/85 0% | 7/1862 0% |
| Breast Carcinoma | 2/144 1% | 9/3264 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
Mutation Distribution
Where MATK is mutated · all tissues, split by cell line vs tissue
How many mutations in MATK were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,739 mutations in MATK
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|